Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

244.00 -0.56 (-0.23%)

Streaming Delayed Price Updated: 11:14 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven...

Via MarketMinute

Is Johnson & Johnson a Buy, Sell, or Hold in 2026? ↗

February 10, 2026

This reliable dividend payer may be just what the doctor ordered.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property Lawsuit

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗

February 09, 2026

Via MarketBeat

Topics ETFs

Johnson & Johnson (NYSE:JNJ) Stands Out as a High-Quality Dividend Aristocrat for Income Investors ↗

February 07, 2026

Via Chartmill

Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? ↗

February 04, 2026

Via The Motley Fool

Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study ↗

February 09, 2026

Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.

Via Benzinga

What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill. ↗

February 08, 2026

These companies pay very healthy dividends.

Via The Motley Fool

Topics Bonds

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Johnson & Johnson Is A Resilient Blue-Chip Stock And It Just Hit New All-Time Highs ↗

February 06, 2026

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs.

Via Talk Markets

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

February 06, 2026

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from...

Via Barchart.com

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition

February 05, 2026

In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for...

Via MarketMinute

Topics Supply Chain

Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)

February 05, 2026

February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...

Via Finterra

Topics Product Recall World Trade

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery

February 02, 2026

As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3...

Via TokenRing AI

Topics Artificial Intelligence

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Via The Motley Fool

Topics Intellectual Property

All It Takes Is $13,000 Invested in Each of These 2 Dividend Kings to Help Generate $1,000 in Passive Income in 2026 ↗

February 01, 2026

Consumer staples stocks being out of favor is an impeccable buying opportunity for value investors.

Via The Motley Fool

Topics Earnings

3 Vanguard ETFs to Buy to Protect Your Portfolio from a Potential Stock Market Crash ↗

February 01, 2026

These Vanguard funds won't necessarily keep you from losing money if the market crashes. But they can help cushion the blow.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗

January 31, 2026

These market giants make great long-term investments.

Via The Motley Fool

1 Super-Safe High-Yield Dividend King Stock to Buy Even if There's a Stock Market Sell-Off in 2026 ↗

January 31, 2026

Near a 12-year low, Kimberly-Clark may be one of the best deep value stocks for income investors to buy in 2026.

Via The Motley Fool

Topics Artificial Intelligence Economy World Trade

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗

January 30, 2026

Johnson & Johnson is a picture of stability.

Via The Motley Fool

Topics Intellectual Property

Economic Alarm Bells: LEI Index Slips 0.3% as US Economy Navigates a Fragile 2026 Start

January 30, 2026

The Conference Board’s Leading Economic Index (LEI) recorded a 0.3% slip in its latest reading, signaling a cooling trajectory for the United States economy as it enters the new year. This downturn,...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

January 30, 2026

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Via Barchart.com

Topics ETFs World Trade

TSM or NVDA? ↗

January 29, 2026

Taiwan Semiconductor recently put up stellar fourth-quarter numbers, signaling that we've yet to reach peak AI demand. Are we in for another banner year in 2026?

Via The Motley Fool

Topics Artificial Intelligence

The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life

January 28, 2026

In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic...

Via TokenRing AI

Topics Artificial Intelligence Economy

Boston Scientific to Acquire Penumbra for $14.5 Billion in Massive MedTech Consolidation

January 28, 2026

MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra...

Via MarketMinute

Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years ↗

January 28, 2026

And that won't be the end of their growth stories.

Via The Motley Fool

Topics Credit Cards

3 Dividend Stocks to Hold for the Next 20 Years ↗

January 28, 2026

These aren't high-growth businesses, but they're as reliable as they come.

Via The Motley Fool

JNJ Stock Rises On Fresh FDA Approval For Multiple Myeloma Drug ↗

January 27, 2026

FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

Headline News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today